These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35733913)

  • 21. In vitro activity of ceftazidime/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015-17).
    Spiliopoulou I; Kazmierczak K; Stone GG
    J Antimicrob Chemother; 2020 Feb; 75(2):384-391. PubMed ID: 31742604
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Yang Y; Guo Y; Yin D; Zheng Y; Wu S; Zhu D; Hu F
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant
    Sun S; Chen K; Kong X; Tian W; Niu S
    Infect Drug Resist; 2022; 15():2243-2251. PubMed ID: 35510161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019.
    Adámková V; Mareković I; Szabó J; Pojnar L; Billová S; Horvat Herceg S; Kuraieva A; Możejko-Pastewka B
    Eur J Clin Microbiol Infect Dis; 2022 Jun; 41(6):989-996. PubMed ID: 35596097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant
    Manzke J; Stauf R; Neumann B; Molitor E; Hischebeth G; Simon M; Jantsch J; Rödel J; Becker SL; Halfmann A; Wichelhaus TA; Hogardt M; Serr A; Hess C; Wendel AF; Siegel E; Rohde H; Zimmermann S; Steinmann J
    Antibiotics (Basel); 2022 Apr; 11(5):. PubMed ID: 35625189
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Longshaw C; Manissero D; Tsuji M; Echols R; Yamano Y
    JAC Antimicrob Resist; 2020 Sep; 2(3):dlaa060. PubMed ID: 34223017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of
    Mojica MF; De La Cadena E; García-Betancur JC; Porras J; Novoa-Caicedo I; Páez-Zamora L; Pallares C; Appel TM; Radice MA; Castañeda-Méndez P; Gales AC; Munita JM; Villegas MV
    mSphere; 2023 Apr; 8(2):e0065122. PubMed ID: 36877058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meropenem-Vaborbactam Activity against Carbapenem-Resistant
    Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of the Italian infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-IT): activity of ceftazidime/avibactam against Enterobacterales isolated from urine.
    Giani T; Antonelli A; Sennati S; Di Pilato V; Chiarelli A; Cannatelli A; Gatsch C; Luzzaro F; Spanu T; Stefani S; Rossolini GM
    J Antimicrob Chemother; 2020 Apr; 75(4):979-983. PubMed ID: 31958125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates].
    Hoşbul T; Aydoğan CN; Kaya S; Bedir O; Gümral R; Albay A
    Mikrobiyol Bul; 2022 Apr; 56(2):218-229. PubMed ID: 35477226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.
    Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF
    J Antimicrob Chemother; 2018 Oct; 73(10):2777-2781. PubMed ID: 30010951
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Karlowsky JA; Lob SH; Akrich B; DeRyke CA; Siddiqui F; Young K; Motyl MR; Hawser SP; Sahm DF
    JAC Antimicrob Resist; 2023 Feb; 5(1):dlad003. PubMed ID: 36694850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility of Gram-negative isolates collected in South Korea to imipenem/relebactam and comparator agents-SMART 2018-21.
    Karlowsky JA; Wise MG; Chen WT; Siddiqui F; Young K; Motyl MR; Sahm DF
    JAC Antimicrob Resist; 2024 Feb; 6(1):dlad149. PubMed ID: 38161963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021).
    Sader HS; Mendes RE; Carvalhaes CG; Kimbrough JH; Castanheira M
    Open Forum Infect Dis; 2023 Feb; 10(2):ofad046. PubMed ID: 36846612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.
    Wang X; Zhao C; Wang Q; Wang Z; Liang X; Zhang F; Zhang Y; Meng H; Chen H; Li S; Zhou C; Li H; Wang H
    J Antimicrob Chemother; 2020 Jul; 75(7):1850-1858. PubMed ID: 32154866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres.
    Hirsch EB; Brigman HV; Zucchi PC; Chen A; Anderson JC; Eliopoulos GM; Cheung N; Gilbertsen A; Hunter RC; Emery CL; Bias TE
    J Glob Antimicrob Resist; 2020 Sep; 22():689-694. PubMed ID: 32353524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
    Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
    J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).
    Sader HS; Flamm RK; Carvalhaes CG; Castanheira M
    Diagn Microbiol Infect Dis; 2020 Mar; 96(3):114833. PubMed ID: 31924426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftazidime/Avibactam and Other Commonly Used Antibiotics Activity Against Enterobacterales and
    Zalas-Więcek P; Prażyńska M; Pojnar Ł; Pałka A; Żabicka D; Orczykowska-Kotyna M; Polak A; Możejko-Pastewka B; Głowacka EA; Pieniążek I; Pawlik M; Grys M; Bogiel M
    Infect Drug Resist; 2022; 15():1289-1304. PubMed ID: 35370409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.